AzTrials
AzTrials

Adolescent HIV InfectionATTACH-ScaleNCT06924073

Scale-up of an Evidence-based Adolescent Transition Package to Support Transitional Care Among Youth Living With HIV

A study testing ATP-Youth Enhanced Strategy (ATP-YES) in people with Adolescent HIV Infection and Transition to Adult Care, run by University of Washington at 25 sites in Kenya.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Ending the HIV epidemic for youth living with HIV will require implementation and optimization of evidence-based interventions that address barriers to treatment. The proposed implementation study will test a youth-led data-driven implementation strategy to scale-up an evidence-based Adolescent Transition Package… Read more about this study

Who is it for?
Ages 10 years and olderHealthy volunteers can take part
What is being tested?
ATP-Youth Enhanced Strategy (ATP-YES)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,920 participants
Where
25 sitesKenya
Study dates
16 Oct 2025to 30 Jan 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 10 years and older
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • Healthcare providers
  • ≥18 years of age
  • Employed at one of the 32 facilities in the RCT
  • Provides HIV services to adolescents affiliated within their clinic Adolescents and youth living with HIV
  • Between 15-24 years of age (focus group discussions, surveys) or between 10-24 years of age (offered the intervention)
  • Receives HIV clinical care at one of the clinics included in the study
  • Attended clinic ≥1 time following intervention implementation

Who cannot join

  • Any individual who meets the following criteria will be excluded from participation in this study:
  • Conditions that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study

Trial locations and contacts

25 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Kristin M Beima-Sofie, PhD, MPH contact

206-685-8332

beimak@uw.edu

Irene Njuguna, MBChB, MPH, PhD contact

irenen@uw.edu

25 sites in 1 country

Kenya25 sites, 25 recruiting
  • Awendo Sub County Hospital

    Awendo

    Medical Supervisor, 254-723227477, mnn3@uw.edu

    Recruiting
  • Uriri Sub County Hospital

    Awendo

    Medical Supervisor, 254-701969623, mnn3@uw.edu

    Recruiting
  • Gatundu Level 5 Hospital

    Gatundu

    Medical Supervisor, 254-723600862, gatundul4h@gmail.com

    Recruiting
  • Kiambu County Referral Hospital

    Kiambu

    Medical Supervisor, 254-723273546, kiambudistricthospital@gmail.com

    Recruiting
  • Wangige Sub-County Hospital

    Kiambu

    Medical Supervisor, 254-723243427, mnn3@uw.edu

    Recruiting
  • Kikuyu (PCEA) Hospital

    Kikuyu

    Medical Supervisor, 254-720921267, cmo@pceakikuyuhospital.org

    Recruiting
  • Nazareth Hospital

    Limuru

    Medical Supervisor, 254-722405166, Info@nazarethhospital.or.ke

    Recruiting
  • Arombe Dispensary

    Migori

    Medical Supervisor, 254-797603497, mnn3@uw.edu

    Recruiting
  • Dede Health Centre

    Migori

    Medical Supervisor, 254-727629677, mnn3@uw.edu

    Recruiting
  • Migori County Referral Hospital

    Migori

    Medical Supervisor, 254-794456890, mnn3@uw.edu

    Recruiting
  • St Joseph Mission Hospital (Ombo)

    Migori

    Medical Supervisor, 254-723628148, mnn3@uw.edu

    Recruiting
  • Baraka Dispensary (Nairobi)

    Nairobi

    Medical Supervisor, 254-711639234, mnn3@uw.edu

    Recruiting
  • Embakasi Health Centre

    Nairobi

    Medical Supervisor, 254-202318794, mnn3@uw.edu

    Recruiting
  • Kenyatta National Hospital/University of Nairobi

    Nairobi

    Teresiah N Maina, +254-020-723-448-552, trenjambs@gmail.com

    Dalton Wamalwa, dalton.wamalwa@uonbi.ac.ke

    Not yet recruiting
  • Mama Lucy Kibaki Hospital

    Nairobi

    Medical Supervisor, 254-208022676, medsupnedh@yahoo.com

    Recruiting
  • Mbagathi District Hospital

    Nairobi

    Medical Supervisor, 254-202724712, mbagathihosp@gmail.com

    Recruiting
  • Mukuru Health Centre

    Nairobi

    Medical Supervisor, 254-710802246, mnn3@uw.edu

    Recruiting
  • Pumwani Maternity Hospital

    Nairobi

    Medical Supervisor, 254-778564272, pumwanimaternityhospital@gmail.com

    Recruiting
  • Tabitha Medical Clinic

    Nairobi

    Medical Supervisor, 254-725407044, joy.barnice@cfkafrica.org

    Recruiting
  • Umoja Health Center

    Nairobi

    Medical Supervisor, 254-710628919, mnn3@uw.edu

    Recruiting
  • Rongo Sub County Hospital

    Rongo

    Medical Supervisor, 254-713463946, mnn3@uw.edu

    Recruiting
  • Verna Health Centre

    Rongo

    Medical Supervisor, 254-705574747, mnn3@uw.edu

    Recruiting
  • Ruiru Sub-County Hospital

    Ruiru

    Medical Supervisor, 254-714799080, wanjirupatience35@gmail.com

    Recruiting
  • Kiandutu Health Centre

    Thika

    Medical Supervisor, 254-720311498, mnn3@uw.edu

    Recruiting
  • Thika Level 5 Hospital

    Thika

    Medical Supervisor, 254-723884069, alengawek@gmail.com

    Recruiting

Other trials in Kenya

About this study

Ending the HIV epidemic for youth living with HIV will require implementation and optimization of evidence-based interventions that address barriers to treatment. The proposed implementation study will test a youth-led data-driven implementation strategy to scale-up an evidence-based Adolescent Transition Package (ATP) aimed at improving transition processes and post-transition clinical outcomes for youth living with HIV in Kenya. Clinics will be randomized to receive standard of care implementation through trainer of trainers or the youth-led data-driven implementation strategy alongside trainer of trainers. We will study whether the enhanced implementation strategy improves the number of youth who receive the ATP, the number of providers that initially chose to use the ATP, and the consistency with which the ATP is used over time. We will also evaluate the cost of the ATP and whether the ATP improves health outcomes among youth living with HIV, including viral suppression and retention in care. Healthcare workers at study sites will complete surveys, focus group discussions, interviews, and participate in continuous quality improvement processes. Youth will participate in surveys and focus groups, and have their routine medical records abstracted.

Read the detailed description

The proposed project extends the team's previously conducted cluster randomized controlled trial, the Adolescent Transition to Adult Care (ATTACH) study (NIH R01HD089850-01; PI John-Stewart). This new R01 tests an implementation strategy to improve scale up of an Adolescent Transition Package (ATP), developed during the previous clinical trial, within health facilities in Kenya and evaluate the cost-effectiveness and budget impact of the implementation strategy. Primary outcomes include measuring intervention uptake and delivery outcomes using the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) framework, factors influencing implementation, clinical outcomes, and cost.

The ATP is a healthcare worker (HCW) delivered toolkit that supports the transition from pediatric to independent care for youth living with HIV (YLH). The ATP was developed by the ATTACH study, working in partnership with the Kenya Ministry of Health and other key collaborators leading treatment and care provision in Kenya. The ATP is designed to support transition to adult care for YLH and provide YLH with the knowledge and skills needed to independently manage HIV. The ATP combined two evidence-based interventions from other contexts (Namibia and the United States) and adapted them to better meet Kenyan patient, provider and health system needs. The ATP was tested in a randomized controlled trial of 20 clinics in 4 counties in Kenya (ATTACH study), and shown to significantly improve readiness to transition among YLH in intervention sites compared to those in the control. HCWs and YLH appreciated the content and design of the ATP as they found it feasible and acceptable for routine clinic use.

During this scale up focused R01, the ATP will be administered at the clinic level by existing HCWs during routine YLH clinic visits, as in the original trial. In all participating clinics, all eligible adolescents aged 10-24 years will have medical record data abstracted, and older YLH (ages 15-24) will be offered the opportunity to participate in surveys and qualitative data collection. HCWs from participating clinics will provide feedback on implementation throughout the study and work to optimize delivery of the ATP within their clinic settings.

The ATTACH-Scale study includes implementation of the ATP in 32 clinics. The 32 study sites for this R01 will be selected from a large list of eligible facilities, and specific clinics will be selected by prioritizing high HIV volume clinics (>50 YLH per clinic), existing collaborations (ex: ATTACH study sites), and MoH priorities. Selection of intervention and control sites will be done using stratified randomization, balancing for county and model of HIV care in the clinic, by a biostatistician based at the University of Washington. The units of analysis vary by study aim, and are either at the level of the HCW, YLH, or clinic, depending on the specific aim and outcome being assessed.

Specific details for each study aim are described below.

Aim 1 (SCALE-UP): Using an effectiveness-implementation hybrid III design, the study will test the impact of ATP scale-up using the Kenya MoH standard of care (SoC) implementation strategy (Trainer of Trainers [ToT]) versus an enhanced scale-up implementation strategy that includes the SoC plus youth-led data- driven intervention adaptations (ATP-YES). ATP-YES is a multi-component youth led package that incorporates weekly data assessments, data review and adaptation meetings, and cross collaborative learning across intervention sites. In total, 32 HIV clinics (4 counties, 8 per county) will be randomized 1:1 to 36 months of ATP-YES or SoC alone. The Reach, Effectiveness, Adoption, Implementation and Maintenance [RE-AIM] framework will be used to evaluate and compare ATP implementation and guide real-time ATP adaptations. Specifically, ATP reach (YLH exposed to ATP), effectiveness (intervention effect on transition readiness, viral suppression and retention), adoption (proportion of HCWs implementing the ATP), implementation (fidelity to ATP processes), and maintenance (continued use post-trial) will be measured at each study site and compared between intervention and control arms. The Consolidated Framework for Implementation Research (CFIR) will be used to understand the role of context on how and why the ATP-YES strategy is or is not successful. The Framework for Reporting Adaptations and Modifications to Evidence-based Implementation Strategies (FRAME-IS) will be used to systematically study adaptations to the ATP and ATP-YES implementation strategy.

Aim 2 (COSTING): Simultaneously with Aim 1, program costs will be captured and the budget impact of ATP-YES will be compared between intervention and control sites. Micro costing, involving HCW interviews and time and motion observations, will be used to estimate the incremental costs of implementing the ATP-YES strategy and develop a model to project the health impact (HIV deaths and morbidity averted) and financial costs of ATP-YES compared to SoC.

Impact: The study will determine whether the ATP-YES can be used to effectively and affordably support implementation of the ATP in Kenya. The study team hypothesizes that this implementation strategy will improve uptake, integration, and delivery of the ATP within existing YLH clinics.

Alongside study aims, this project will engage communities, build capacity for IS research among youth, program implementers and policy-makers, and participate in collaborative science. The project includes collaboration with MOH in Kenya to ensure transition tools and implementation processes align with and integrate MOH priorities and strategies. The study also includes creation of a youth advisory board and engagement of policy-makers, HCWs, program implementers and other key stakeholders throughout the entirety of the study. Finally, the study supports youth to gain research skills and build capacity for conducting research through their leadership roles in ATP-YES, involvement in youth mentorship programs, and the youth advisory board.

Being tested
ATP-Youth Enhanced Strategy (ATP-YES)
Keywords
Adolescent HIV, Transition to Adult Care, Scale-up, Implementation science, implementation strategy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ATP-Youth Enhanced Strategy (ATP-YES)Other

    ATP-YES is a multi-component youth led implementation strategy that incorporates data audits and feedback, cyclical small tests of change and learning collaboratives

Study groups in NCT06924073
Study groupRoleWhat they receive
Training of trainersNo interventionSites assigned to the standard of care (SoC) control arm will receive cascading training of trainers (ToTs) and cascade training to sites for supporting scale-up of the ATP
Youth Enhanced Implementation Strategy (ATP-YES)ExperimentalSites assigned to the intervention arm will receive the ATP-YES implementation strategy, a multi-component youth led implementation strategy that incorporates data audits and feedback, cyclical small tests of change and learning collaboratives, to support scale-up of the ATP
Receives: Other: ATP-Youth Enhanced Strategy (ATP-YES)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Reach

    Proportion of youth living with HIV ages 15-24 years exposed to the ATP intervention

    Measured: From enrollment through 6 months post study end (42 months)

  2. Effectiveness: Successful Transfer

    Proportion of youth living with HIV who attend first adult clinic visit

    Measured: From enrollment through 6 months post study end (42 months)

  3. Effectiveness: Retention

    Number of scheduled clinic visits youth living with HIV attend in the year after transition to adult care

    Measured: From enrollment through 6 months post study end (42 months)

  4. Adoption

    Proportion of health providers in youth HIV clinics who deliver the ATP

    Measured: From enrollment through 6 months post study end (42 months)

Secondary outcomes (5)
  1. Effectiveness: Transition Readiness

    Change in transition readiness scores

    Measured: From enrollment through 6 months post study end (42 months)

  2. Effectiveness: Viral Suppression

    Proportion of youth living with HIV who are virally suppressed 12 months after transition to adult clinics

    Measured: From enrollment through 6 months post study end (42 months)

  3. Implementation: Fidelity to ATP

    Proportion of facilities that deliver the ATP as designed

    Measured: From enrollment through 6 months post study end (42 months)

  4. Implementation: Fidelity to ATP-YES

    Proportion of facilities that deliver the ATP-YES as designed in intervention clinics

    Measured: From enrollment through 6 months post study end (42 months)

  5. Maintenance

    Proportion of clinics that continue use the ATP as designed 6 months post study

    Measured: From study end (36 months) through 6 months post study end (42 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Apr 2025
  2. Study start16 Oct 2025
  3. Primary completion30 Jan 2029 (estimated)
  4. Study completion30 Jan 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
1,920 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06924073
Sponsor's protocol ID
STUDY00020373
Other IDs
1R01MH136897
Acronym
ATTACH-Scale
Status last verified
Nov 2025
First submitted
4 Apr 2025
Last updated
14 Nov 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The research community will have access to data when the award ends. De-identified individual and aggregate survey data (including raw and recoded data) will be deposited to NDA starting 12 months after the award begins and will be deposited every six months thereafter following the usual NDA data submission dates. As required by NDA, studies will also be created that contain the data used for every publication. Documentation to be made publicly available to the research community will include PDF, Word, and Excel documents containing survey instruments, interview guides, data collection protocols, codebooks for surveys and qualitative analysis, and code used in survey data analyses. Abstracted medical records will be used as secondary data and will not be shared. Transcripts from focus group discussions and interviews with providers, and voice recordings of focus groups or interviews from youth and providers will not be shared to protect participant privacy.

Questions about this trial

What is this clinical trial studying?

A study testing ATP-Youth Enhanced Strategy (ATP-YES) in people with Adolescent HIV Infection and Transition to Adult Care, run by University of Washington at 25 sites in Kenya.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 14 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 25 sites in Kenya. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Kristin M Beima-Sofie, PhD, MPH (206-685-8332, beimak@uw.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Reach (time frame: From enrollment through 6 months post study end (42 months)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in